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Background: Remifentanil-induced hyperalgesia (r-IH) involves an imbalance in the
inhibitory and excitatory systems. As the transcranial Direct Current Stimulation (tDCS)
modulates the thalamocortical synapses in a top-down manner, we hypothesized that
the active (a)-t-DCS would be more effective than sham(s)-tDCS to prevent r-IH. We
used an experimental paradigm to induce temporal summation of pain utilizing a
repetitive cold test (rCOLDT) assessed by the Numerical Pain Score (NPS 0-10) and
we evaluated the function of the descending pain modulatory system (DPMS) by the
change on the NPS (0–10) during the conditioned pain modulation (CPM)-task (primary
outcomes). We tested whether a-tDCS would be more effective than s-tDCS to improve
pain perception assessed by the heat pain threshold (HPT) and the reaction time during
the ice-water pain test (IPT) (secondary outcomes).
Methods: This double-blinded, factorial randomized trial included 48 healthy males,
ages ranging 19–40 years. They were randomized into four equal groups: a-tDCS/saline,
s-tDCS/saline, a-tDCS/remifentanil and s-tDCS/remifentanil. tDCS was applied over the
primary motor cortex, during 20 min at 2 mA, which was introduced 10 min after starting
remifentanil infusion at 0.06 µg·kg−1·min−1 or saline.
Results: An ANCOVA mixed model revealed that during the rCOLDT, there was a
significant main effect on the NPS scores (F = 3.81; P = 0.01). The s-tDCS/remifentanil
group presented larger pain scores during rCOLDT, [mean (SD) 5.49 (1.04)] and
a-tDCS/remifentanil group had relative lower pain scores [4.15 (1.62)]; showing its
blocking effect on r-IH. a-tDCS/saline and s-tDCS/saline groups showed lowest pain
scores during rCOLDT, [3.11 (1.2)] and [3.15 (1.62)], respectively. The effect of sedation
induced by remifentanil during the rCOLDT was not significant (F = 0.76; P = 0.38).
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Remifentanil groups showed positive scores in the NPS (0–10) during the CPM-task,
that is, it produced a disengagement of the DPMS. Also, s-tDCS/Remifentanil compared
to a-tDCS showed lower HPT and larger reaction-time during the IPT.
Conclusion: These findings suggest that effects of a-tDCS prevent the summation
response induced by r-IH during rCOLDT and the a-tDCS blocked the disengagement
of DPMS. Thereby, tDCS could be considered as a new approach to contra-regulate
paradoxical mechanisms involved in the r-IH. Clinical trials identification: NCT02432677.
URL:https://clinicaltrials.gov/.
Keywords: tDCS, hyperalgesia, remifentanil, pain threshold, CPM
INTRODUCTION
Opioids are the most effective analgesics to treat moderate to
severe acute and chronic pain. However, growing evidence shows
that opioids can elicit unexpected changes in pain sensitivity. This
hyperalgesia induced by opioids (OIH) may extend beyond the
postoperative period and can lead to the development of chronic
pain persisting for months (Salengros et al., 2010). Considering
that OIH is a paradoxical response, a better comprehension
about its mechanism could help the clinician plan preventive
approaches to reduce acute postoperative pain, and possibly to
reduce the incidence of persistent post-surgical pain potentially
related to the OIH, which ranges 16–70% (Salengros et al.,
2010). A recent systematic review that involved 27 studies
and 1494 patients add evidence of OIH in humans (Fletcher
and Martinez, 2014), which cause a significant increase in
postoperative pain intensity at rest persisting 24 h after surgery.
Another study found that patients undergoing thoracotomy
who received high-dose remifentanil without epidural analgesia
experienced a three times larger area of allodynia compared
to low-dose infusion of remifentanil (Salengros et al., 2010).
At 6 months followed-up, a higher incidence of chronic pain
resembling neuropathic pain was observed in those receiving
high doses of remifentanil (Salengros et al., 2010). Although
there is a mixed result, pre-clinical and clinical evidence
has demonstrated that remifentanil might induce hyperalgesia
(r-IH) either with acute or chronic use (Kim et al., 2014;
Stoicea et al., 2015; Yu et al., 2016). The most reliable proof
of opioids producing hyperalgesia (OIH) in humans comes
from opioid infusions in healthy volunteers (Fishbain et al.,
2009).
According to previous reports, morphine blocks the diffuse
noxious inhibitory control (DNIC) effects in rats (Bouhassira
et al., 1992, 1993) and healthy humans (Le Bars et al., 1992)
in a naloxone-reversible fashion (Le Bars et al., 1981; Willer
et al., 1990). Another study showed that patients with chronic
pain treated with oral opioids exhibited less capacity to inhibit
pain signals compared to non-treated patients (Chu et al.,
2006). Specifically related to remifentanil, an attractive hypothesis
is that its effects involve the N-methyl-D-aspartate (NMDA)
receptors (NR1A/2A and NR1A/2B), and hence, it induces a
dysfunction of the descending pain modulatory system (DPMS),
which is rich in both inhibitory mu-opioid and excitatory
NMDA receptors (Hahnenkamp et al., 2004). In fact, in one
experimental study in humans, S-ketamine abolished the r-IH
(Joly et al., 2005). Also, knockout mice without µ-, δ-, or κ-opioid
receptors develop thermal hyperalgesia when exposed to acute
or chronic fentanyl use (Celerier et al., 2001). Finally, when
morphine-6β-glucuronide (a metabolite with µ-receptor agonist
activity) was administered concurrently with the opioid receptor
antagonist naloxone, it leads to OIH by an opioid receptor-
independent mechanism (Van Dorp et al., 2009). Despite
the growing evidence of OIH, the results are heterogeneous,
thus revealing a persistent gap to study whether top-down
modulatory approaches can improve the inhibitory function of
the descending corticospinal pathways since their dysfunction
mediate this paradoxical effect.
As aforementioned, OIH involves a dysfunction in the
thalamus cortical pathways as well as in the DPMS. Thereby,
transcranial direct current stimulation (tDCS) is a promising
approach to contra-regulate OIH, because it modulates the
thalamocortical synapses in a top-down manner within pain
pathways (Stagg et al., 2009). The tDCS effect depends on
the polarity, positioning, and size of electrodes, as well as
the duration and intensity of the current flow (DaSilva et al.,
2011). It has been effective either in acute postoperative pain
(Ribeiro et al., 2017) and chronic pain (i.e., trigeminal neuralgia,
phantom pain, fibromyalgia, etc.) (Fregni et al., 2006; Bolognini
et al., 2013). Although its effect on pain is not completely
understood, it downregulates the emotional component of the
pain experience while alleviating pain via activation of the
descending pain suppression system (Hadjipavlou et al., 2006).
Indeed, the majority of trials has rationalized that the tDCS effect
involves changes in “brain function” induced by excitatory or
inhibitory boosts. According to studies of rodent brain slices
in vitro, tDCS can affect long-term-potentiation (LTP) dependent
on N-methyl D-aspartate (Giordano et al., 2017). Also, its
neuroplastic changes involves a regulation of a broad variety of
different interneurons and neurotransmitters, such as opioidergic
(Nitsche et al., 2003; Filmer et al., 2014), GABAergic (Nitsche
et al., 2004), glutaminergic (Nitsche et al., 2003), cholinergic (Kuo
et al., 2007), serotonergic (Nitsche et al., 2009), and dopaminergic
(Nitsche et al., 2006).
In this sense, to investigate the therapeutic effect of tDCS in
OIH, we used accurate tests to evoke OIH, as well appropriate
approaches to detect and measure its presence. According to
previous studies, OIH is dependent on the nature of the pain
model used, and the cold pain test has demonstrated to be the
Frontiers in Pharmacology | www.frontiersin.org 2 February 2018 | Volume 9 | Article 94
fphar-09-00094 February 15, 2018 Time: 19:12 # 3
Braulio et al. tDCS Effect Blunt Remifentanil-Induced Hyperalgesia
most sensitive of the methods tested in detecting opioid-related
hyperalgesia (Krishnan et al., 2012). Thus, due to the complex
mechanisms of pain, innovative interventions should be tested
in an experimental paradigm that allows us to characterize the
etiological components of pain (nature, localization, intensity,
frequency, and duration of the trigger to evoke pain). Hence,
stimuli to elicit pain should be suitable to activate the pain
pathways, while it being non-invasive and permit its repeated
application (Olesen et al., 2012).
Taking this into account, and considering how tDCS
modulates the thalamocortical synapses in a top-down manner,
we hypothesized that the active (a)-t-DCS would be more
effective than a sham(s)-tDCS to prevent r-IH. We used an
experimental paradigm to induce temporal summation of pain
utilizing a repetitive cold test (rCOLDT) assessed by the
Numerical Pain Score (NPS 0-10) and we evaluated the function
of the DPMS by the change on the NPS (0–10) during the
conditioned pain modulation (CPM)-task (primary outcomes).
We tested whether a-tDCS would be more effective than s-tDCS
to improve pain perception assessed by the heat pain threshold
(HPT) and the reaction time during the ice-water pain test (IPT)
(secondary outcomes).
MATERIALS AND METHODS
Design Overview, Settings, and
Participants
This is a randomized, double-blinded, parallel clinical
trial, conducted by the CONSORT guidelines. This study
was registered at the ClinicalTrials.gov on April 6, 2015
(NCT02432677, investigator WC.). The Research Ethics
Committee at the Hospital de Clinicas de Porto Alegre approved
this protocol. All volunteers provided their written informed
consent before participating in the study. The Experimental
design, assessments, and interventions are presented in
Figure 1.
Study Subjects
The volunteers were recruited from the general population by
advertisement postings in public places in the Porto Alegre
area. Participants were considered eligible to participate if
they were male, right-handed, and between 19 and 40 years
of age. They were screened for eligibility by phone to
answer a structured questionnaire that assessed the following
variables: sleep disorders, chronic diseases, substance abuse,
or alcohol use in the past 6 months, use of psychotropic
drugs, history of brain surgery, tumor, stroke or implantation
of intracranial metal. Individuals responding affirmatively to
any of these questions, those with contraindications for tDCS
(Fregni et al., 2015) or if they presented a score on the Beck
Depression Inventory (BDI) higher than 13 were excluded
(Warmenhoven et al., 2012). We include males only to exclude
the influence of the cyclical fluctuation of gonadal steroids
during the menstrual cycle on pain measures (Stefani et al.,
2012).
Interventions
Remifentanil and saline (NaCl 0.9%) placebo solutions were
prepared in coded (indistinguishable) infusion syringes attached
to a continuous syringe pump with a dose of 0.06 µg·kg−1·min−1
(Gustorff et al., 2001). Except for T0, all other pain stimuli in the
experiment had a concomitant infusion of remifentanil or saline.
The tDCS anode, active or sham, was positioned over the
primary motor cortex (M1), and the cathode was placed on
the right supraorbital region. tDCS was introduced 10 min
after the beginning of infusion (remifentanil or saline) to
ensure adequate concentration at the effector site according to
pharmacokinetic characteristics of the drug. Each tDCS session
lasted for 20 min. The rubber electrodes were inserted into a
35-cm2 sponge (moistened with NaCl). The current flow time and
the intensity were set at 20 min and 2 mA, respectively. In sham-
tDCS, the current flow was applied only for 30 s and turned off,
to prevent the subjects from recognizing it from active tDCS. The
timeline of study is presented in Figure 2.
Outcomes
The primary outcome was the DPMS function as assessed by
the NPS (0–10) during the QST applied simultaneously with a
painful heterotopic stimulus, the rCOLDT and the change on the
NPS (0–10) during the CPM-task. The secondary outcomes were
the ascendant pain pathway and cortical involvement which was
assessed by the HPT and the reaction time evaluated by the area
under the curve using a Visual Analogue Scale (AUCVAS).
Primary Outcomes Assessment
CPM-task
To measure the CPM-task, we assessed the pain intensity during
two tonic HPT test stimuli separated by a CPM-task. To induce a
prolonged pain sensation to trigger CPM we used the HPT. The
CPM-task consisted of immersion of the non-dominant hand
in cold water (zero to 1◦C) for 60 s. The QST procedure was
introduced after 30 s of cold-water immersion over the right
forearm (dominant forearm) using a temperature individually
predetermined to produce a pain score of 6/10 in the NPS during
the pretesting sessions. To determine the CPM, we used the
difference between the pain score on the NPS (0–10) QST during
cold-water immersion (QST+CPM) at the temperature of the
point at which subjects felt 6/10 pain on the NPS scale [during
the initial period (T0)].
Repetitive cold test (rCOLDT)
To examine the temporal summation of the second pain, we used
a trial of three identical nociceptive stimuli to elicit a pain score
of 6/10 in the NPS (test stimulus). A 5 min interval separated
each trial. To produce a standard painful stimulus during each
trial, they had to immerse their non-dominant hand in cold
water (zero to 1◦C) for 60-s. After 30-s of immersion, the test
stimulus (QST) was applied, and they rated their pain on the
NPS (0–10). The increase of 15% on the NPS (0–10) from the
baseline was considered to present hyperalgesia. An accepted
criterion to define a minimally important change on the NPS
(0–10) is a modification of 10–20% (Dworkin et al., 2009). Thus,
we assumed that scores on the NPS (0–10) during the rCOLDT
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FIGURE 1 | Randomization and follow-up of the study subject.
that present an increase of at least 15% or more from the baseline
indicated a presence of hyperalgesia (Dworkin et al., 2009). For
the subsequent analysis, they were categorized into two groups,
according to scores on the NPS (0–10): presence of hyperalgesia
[increase of 15% or more in their pain score from the baseline
(T0)] or absence of hyperalgesia [a change lower than 15% in the
NPS (0–10) during the three trials (T1 to T3)].
Secondary Outcomes Assessment
Heat pain threshold (HPT)
The method of limits with a computer Peltier-based device
thermode (30 mm × 30 mm) was used to assess the HPT
(Schestatsky et al., 2011). The thermode was attached to
the ventral aspect of the mid-forearm. The temperature was
increased at a rate of 1◦C/s, from 32◦C to a maximum of 52◦C.
To determine the mean temperature of the HPT, we performed
three assessments with an inter-stimuli interval of 40 s.
Ice-water pain test (IWPT)
The non-dominant hand was immersed in ice water (0 ± 1◦C)
for a maximum of 120 s. The subjects were asked to continuously
score their maximal pain intensity perceived on a 0–10 cm
electronic visual analog scale (VAS), where 0 represents ‘no pain’
and 10 represents the ‘worst pain imaginable.’ Subjects were
recorded as 120 s if they did not withdraw their hand for the
maximum time. For subsequent analysis of peak pain intensity,
the area under the time curve was considered as well as the mean
pain intensity. If a subject indicated 5 cm pain (i.e., midpoint
between no pain and maximum pain) for 120 s, the AUEC value
was 5 cm ∗ 120 s or 600 cm ∗ second. Higher values of the area
under the effect curve (AUEC) for reaction time (AUECVAS)
indicates longer reaction time response.
Sample Size
The number of subjects in each study group was determined
by the parameters of a previous survey (da Silva et al., 2015).
To achieve 80% power at 1% significance, with a 0.5 variation
coefficient, we need a total of 48 subjects divided into four equal
groups (n = 12) in 1:1:1:1 ratio to test 1 point [Standard deviation
(SD = 2)] mean a difference between groups for the NPS (0–10).
The NPS (0–10) was used to assess both primary outcomes
(rCOLDT and CPM-task).
Randomization and Blinding
The sequence of randomization was generated by a computer
with a fixed block size of 6. Forty-eight subjects were randomly
allocated to receive treatment (a-tDCS/saline, s-tDCS/saline,
a-tDCS/remifentanil, and s-tDCS/remifentanil). Before the
recruitment phase, brown envelopes containing the protocol
materials were prepared. Each envelope was sealed and numbered
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FIGURE 2 | Experimental design. Timeline of each assessment pre and post intervention. The CPM is determined by the score on Numerical Pain Scale (NPST1)
during the test stimulus (T1) minus de score on NPST0 during the conditioned pain stimulus (T0). The T0 is defined applying heat stimulus to provoke 6/10 in the
NPS, which is determined individually before to apply the heterotopic stimulus. To determine the T1 a heat pain stimulus is applied in the dominant arm to provoke
6/10 in the NPS (0–10) when it is used simultaneously, a distant heterotopic nociceptive stimulus, generated by the immersion of non-dominant hand in cold water
(zero to 1◦C) for the 60 s. The area under the effect curve (AUEC) for reaction time (AUECVAS) is assessed during the ice-water pain test (IWPT), where the
nociceptive stimuli were induced by the immersion of their hand in cold water (0 ± 1◦C) for a maximum of 120 s. The repetitive cold test (rCOLDT) was induced by
the immersion of their non-dominant hand in cold water (zero to 1◦C) for the 60 s with a break of 5 min between each the trial.
sequentially and contained an allocated treatment. Only the
individuals responsible for administering the interventions were
not blinded. All other participants were blinded to the allocated
interventions.
Other Instruments and Assessments
Pain catastrophizing was assessed using the validated Brazilian-
Pain Catastrophizing Scale (Sehn et al., 2012). Depression
symptoms were screened using the BDI-II (Warmenhoven
et al., 2012). We used the State-Trait Anxiety Inventory (STAI),
adapted to Brazilian Portuguese, to measure the State-Trait
Anxiety (Kaipper et al., 2010). The clinical assessment of sedation
was determined by simultaneous recordings using a VAS for
sleepiness (VASS 0–100) ranging from zero 0 (completely awake)
to 100 (sleepiness). To assess safety, we used the Systematic
Assessment for Treatment with a-tDCS questionnaire based on
previously reported adverse events.
Statistical Analyses
The differences between groups were examined with the
analysis of variance (ANOVA) for parametric variables or
the Kruskal–Wallis tests for non-parametric distributions.
Categorical variables were examined using chi-square or Fisher’s
exact and Kruskal–Wallis tests. The values are presented as the
mean (standard deviation) or frequency. Continuous variables
were tested for normality using the Shapiro–Wilks test.
A mixed ANCOVA model in which the independent variable
was the time, the intervention (a-tDCS/saline, s-tDCS/saline,
a-tDCS/remifentanil, and s-tDCS/remifentanil), interaction time
vs. the treatment group, and subject identification was used
to analyze the score change on the NPS (0–10) during the
rCOLDT test and the change on the NPS (0–10) during the
CPM-task.
A multivariate covariance analysis (MANCOVA) model was
used to explore effects between the intervention groups in
the multiple outcomes [1-AUECVAS and 1-HPT, the 1-value
(post-intervention minus pre-intervention)]. The effect of all
intervention groups on the outcomes were adjusted by sleepiness.
All analyses were corrected for multiple comparisons using the
Bonferroni test. All analyses were performed with two-tailed
tests. We accepted a type I error of 5%. Statistical analyses
were performed assuming intention-to-treat. The analyses were
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performed with the SPSS version 22.0 (SPSS, Chicago, IL,
United States).
RESULTS
The characteristics were similar across the four groups as shown
in Table 1 (all P-values > 0.1). The incidence of tDCS associated
side effects was reported by <15% of subjects and it was
similar between groups. Itching in several body regions was
reported in two subjects (16.6%) and four subjects (33.3%) in
the a-tDCS/Remifentanil and s-tDCS/Remifentanil, respectively.
Nausea was reported in four subjects (33.3%) and in five
subjects (41.6%) in the a-tDCS/remifentanil and s-tDCS/saline,
respectively. Vomiting was reported in one subject (8.3%) in
the s-tDCS/remifentanil group. However, the frequency of these
adverse effects was not statistically different between groups. The
scores on the VAS (0–100) showed that a-tDCS/remifentanil and
s-tDCS/remifentanil-induced higher sleepiness than the other
groups (P < 0.01, for each comparison) (Table 1).
Treatment Effect on the Primary
Outcome: NPS Score during the rCOLDT
and the Change on NPS (0–10) during
CPM-Task
Mean ± SD and median interquartile (Q25;75) of pain score
on the NPS (0–10) during RCOLDT according to interventions
at pre-intervention (T0), and post-intervention (T1 to T3) are
presented in Table 2. The incidence of hyperalgesia was 22%
in the group that received the a-tDCS/remifentanil compared
to 8.3% in the group that received s-tDCS/placebo; the relative
risk (RR) for the a-tDCS/remifentanil was 2.75 [confidence
interval (CI) 95%, 1.26–5.88]. The incidence of hyperalgesia
in the group that received the s-tDCS/remifentanil was 30.3%
compared to s-tDCS/placebo, the RR for the s-tDCS/remifentanil
was 3.87 [CI 95%, (1.87–8.01)]. The incidence of hyperalgesia in
the group that received the a-tDCS/saline was 11% compared
to s-tDCS/saline, the RR for the s-tDCS/remifentanil was 1.38
(CI 95%, 0.58–3.27). We observed that the RR to show r-IH
increased approximately fourfold when the s-tDCS/remifentanil
was used. Although the a-tDCS combined with remifentanil
reduced the incidence of r-IH in 8%, the RR to induce
hyperalgesia was yet significantly greater than those not receiving
remifentanil.
A mixed ANCOVA model in which the independent variable
was the time, the intervention (a-tDCS/saline, s-tDCS/saline,
a-tDCS/remifentanil, and s-tDCS/remifentanil), interaction time
vs. the treatment group, and subject identification was used
to analyze the score change on the NPS (0–10) during the
rCOLDT test and the change on the NPS (0–10) during the
CPM-task. The mean in the NPS (0–10) during the rCOLDT
is presented in Figure 3. An ANCOVA mixed model revealed
a significant main effect of interventions on the NPS (0–10)
during the rCOLDT (F = 3.81; P = 0.01). The analysis showed
a significant interaction between the group of interventions and
time (F = 2.04; P = 0.04). The time effect was not observed
(F = 1.43; P = 0.23). The effect of the sedation reported on the
NPS (0–10) during the rCOLDT was not significant (F = 0.76;
P = 0.38).
The change within the group was significant in all treatment
groups (P < 0.001, for all comparisons). The mean (SD)
on the NPS (0–10) during the rCOLDT pretreatment vs. the
cumulative pain scores according to marginal means (T1–T3)
in the a-tDCS/remifentanil was 4.62 (1.56) vs. 4.15 (1.55) and
for the s-tDCS/remifentanil group was 4.45 (2.10) vs. 5.49
(1.04), respectively. Whereas, for the a-tDCS/saline, these values
were 4.7 (1.72) vs. 3.11 (1.2) and for the s-tDCS/saline group
these values were 4.62 (1.62) vs. 3.15 (1.62), respectively. The
difference in the mean [CI 95%] within the a-tDCS/remifentanil
group was 0.47 (CI 95%, 0.04 to 0.90), a small effect size
(Cohen’s f = 20.3). The difference in the mean within the
s-tDCS/remifentanil group was−1.04 (CI 95%,−1.63 to−0.44),
a medium effect size (Cohen’s f 2 = 0.49). Whereas in the
a-tDCS/Saline, it was 1.59 (CI 95%, 1.10–2.08), a large effect
size (Cohen’s f 2 = 0.93) and in the s-tDCS/saline it was 1.47
(CI 95%, 1.01–1.93), a medium effect size (Cohen’s f 2 = 0.72).
It is possible to see that the effect size in the groups receiving
remifentanil was determined by the increase in pain scores in the
cumulative pain scores during the treatment, whereas the effect
TABLE 1 | Characteristics of the study sample.
a-tDCS/remifentanil
(n = 12)
s-tDCS/remifentanil
(n = 12)
a-tDCS/saline
(n = 12)
s-tDCS/saline
(n = 12)
P
Age (years) 27.33 (5.08) 26.08 (2.67) 26.09 (3.41) 26.09 (3.41) 0.78
Education (years) 16.33 (4.68) 16.56 (4.67) 16.56 (4.65) 19 (1.3) 0.19
Weight (Kg) 77 (9.53) 73.62 (9.27) 71.5 (7.9) 75.3 (11.7) 0.45
State-anxiety 26.58 (2.34) 24. 0 (8.1) 20.33 (12.6) 20.33 (12.6) 0.53
Trait-anxiety 31.08 (2.6) 30.4 (10.3) 22.08 (7.72) 25.16 (15.5) 0.32
Depressive symptoms on the
Beck Inventory
4.0 (5.1) 2.6 (3.2) 3.70 (3.45) 3.7 (3.45) 0.84
Pain Catastrophizing Scale 5.84 (6.82) 7.67 (9.15) 6.44 (7.78) 4.46 (7.48) 0.31
Cumulative mean of sleepiness
score on VAS throughout the
trials (0–100)
60 (15.22)3,4 57.91 (27.17)3,4 1.25 (3.16)1,2 13.41 (15.92)1,2 0.00
Values are given as the mean (SD) or as a frequency according to the group (n = 48).
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TABLE 2 | Pain score on NPS (0–10) during RCOLDT according to groups: Mean ± SD and median interquartile (Q25;75) pre-intervention (T0) and post-intervention
(T1–T3).
Pain Score on NPS (0–10) during rCOLDT (primary)
Time a-tDCS/remifentanil s-tDCS/remifentanil a-tDCS/saline s-tDCS/saline
n = 12 n = 12 n = 12 n = 12
Mean (SD) Median (Q25−75) Mean (SD) Median (Q25−75) Mean (SD) Median (Q25−75) Mean (SD) Median (Q25−75)
T0 4.5 (1.56) 4 (2; 7) 4.33 (2.10) 4 (1; 8) 4.58 (1.75) 4 (3; 8) 4.5 (1.62) 4.5 (2; 7)
T1 3.92 (1.74) 3.5 (1; 7) 4.95 (2.05) 4 (1; 7) 4.5 (1.5) 5 (2; 7) 4.25 (1.48) 4.5 (2; 6)
T2 4.35 (2.09) 4 (1; 6) 5.45 (1.92) 5 (1; 7) 3.83 (1.34) 3.5 (2; 6) 3.5 (1.78) 3.5 (1; 7)
T3 4.20 (2.49) 4.5 (0; 6) 5.85 (2.45) 5 (1; 8) 3.4 (1.24) 3 (2; 6) 2.92 (1.92) 3.72 (0;7)
OIH defined as an increase equal or higher than 15% on the NPS (0–10) from the T1 to T3
22% (8/36) 31% (11/36) 11% (4/36) 8.33% (3/36)
OIH defined as an increase equal or higher than 15% on the NPS (0–10) from the T1 to T3 (n = 48).
The incidence was calculated considering the number of measures after receiving the intervention (T1–T3, that is three tests per each one of four interventions group,
a total of 36 trials).
FIGURE 3 | The change in NPS (0–10) during rCOLDT, at baseline before
intervention and in three trials after tDCS and continuous infusion of the
remifentanil or placebo in the four experimental groups. The error bars indicate
standard error of the mean. The asterisk (∗) indicates differences between the
remifentanil combined to a-tDCS or sham groups. All comparisons were
performed by a mixed analysis of variance model, followed by the Bonferroni
test for post hoc multiple comparisons. Numerical Pain Scale (NPS 0–10).
size observed when they are receiving a-tDCS or s-tDCS with
saline was determined by a decrease in the pain scores during the
treatment.
The mean in the NPS (0–10) during the CPM-task is
presented in Figure 4. An ANCOVA mixed model revealed
a main effect of interventions on the CPM-task (P < 0.05)
[F = (7.95; 3) = P < 0.001)]. Also, there is a significant effect of
time (F = 17.01; P < 0.001) and a significant interaction between
intervention and time F = (3.75; P < 0.001). The sleepiness level
influenced the NPS during the CPM-task (F = 7.95, P < 0.001).
The change on the NPS (0–10) during the CPM-task in groups
receiving remifentanil showed positive values on the NPS scores,
that is, it produced a disengagement of the DPMS.
FIGURE 4 | The change in NPS (0–10) during CPM-task, before intervention
and immediately after in the four experimental groups. The error bars indicate
standard error of the mean. Numbers show differences between four
treatment groups. All comparisons were performed by a mixed analysis of
variance model, followed by the Bonferroni test for post hoc multiple
comparisons. Numerical Pain Scale (NPS 0–10).
Treatment Effects on the Time Reaction
HPT and the AUECVAS for Pain
(Secondary Outcomes)
Patients receiving (a-tDCS/remifentanil), (s-tDCS/remifentanil),
and (a-tDCS/saline) showed a greater HPT compared to
(s-tDCS/saline). Their effect size assessed by the SMD
within the (a-tDCS/remifentanil) group was 0.85 while the
(s-tDCS/remifentanil) was 0.37. That is, the s-tDCS/remifentanil
showed lower HPT compared to a-tDCS combined with the
remifentanil or saline (Table 2). A MANCOVA analysis revealed
a significant relationship between the intervention groups and
the HPT as well as in the AUECVAS [Hotelling’s Trace = 0.78,
F(9) = 3.41, P < 0.001]. The power of this analysis was 98%.
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Sleepiness was inversely correlated with the response to the
IPT assessed by the AUECVAS, in the sense that more sleepiness
was associated with greater reaction time. The sleepiness had a
medium effect size (Cohen’s f 2 = 0.31) for the pain measured
by AUECVAS (r-squared = 0.07, standard β coefficient = −2.72,
t =−0.58, both P< 0.001). While the Sleepiness level had a small
effect size for the HPT (Cohen’s f 2 = 0.09) (r-squared = 0.07,
standard β coefficient = 0.02, t = 2.16, both P < 0.001). The
multivariate model is presented in Table 3.
DISCUSSION
The main results of this study can be summarized by three major
findings: (1) we showed that r-IH involves the dysfunction of
the inhibitory pathways or up-regulation of the pain-facilitating
pathways. This effect was demonstrated by the disengagement of
the DPMS measured by the change in the NPS (0–10) during the
CPM-task and by the summation effect on pain scores during
the rCOLDT; (2) a-tDCS blocks r-IH. (3) a-tDCS/saline (as
compared with s-tDCS/saline) has no effect on pain modulation
during the rCOLDT in healthy subjects (likely due to a floor
effect). Finally, according to the AUECVAS measurements,
adjusted by the sleepiness, the remifentanil group showed a
longer reaction time during the IPT compared to the other groups
while the a-tDCS improved the HPT.
a-tDCS induced a large size effect to prevent r-IH, an effect
with a statistical significance and further clinical relevance,
especially because opioids are a powerful tool in the treatment
of pain. Also, because OIH has been described with acute and
chronic exposure, even using different types of opioids at high
and low doses (Chen, 2014). Thereby, r-IH may be explained
by a hyperexcitability of the dorsal horn neurons leading to an
enhanced pain perception (Porreca et al., 2002). Also, according
to previous reports, an increase of mµ-opioid receptor binding
may decrease the ability to recruit endogenous opioids (Zubieta
et al., 2003) and paradoxically increase the pain intensity or
sensitivity (Lee et al., 2011). Another study observed that a
high-dose of remifentanil decreased the mechanical hyperalgesia
threshold and enhanced pain intensity (Lee et al., 2013).
Additionally, previous studies provided convincing evidence that
the mechanisms of OIH are a consequence of NMDA receptor
activation, an increase of spinal excitatory neuropeptides induced
by an increase of spinal dynorphins such as calcitonin gene-
related peptide (CGRP) leading to a reduction in the reuptake
of neurotransmitters that mediate nociception such as glutamate
and substance P (Youssef et al., 2015).
The effect of tDCS mitigates part of the dysfunction in pain
pathways induced by remifentanil as displayed by its effect on
the NPS during the rCOLDT. This result fits nicely with the
putative effects of tDCS in chronic neuropathic pain (Maarrawi
et al., 2013). In this condition, it is believed that a lack of
afferent stimuli may over-activate thalamic centers resulting in
over processing of any sensory stimulus (Bolognini et al., 2013).
Primary motor cortex stimulation during a-tDCS can re-establish
this deafferentation partially. Our findings suggest that r-IH has a
similar effect of blocking afferent sensory processing (inducing
similar mechanisms of central sensitization), which a-tDCS
seems to block. According to anatomical and electrophysiological
data, the caudal medulla sub nucleus reticular dorsal (SRD)
in the spinal bulb spinal loops are preferentially or exclusively
activated by nociceptive stimuli (Wei et al., 2012). Hence, the
responses of SRD neurons to noxious stimuli depend on the
intensity and spatiotemporal features of the noxious stimuli, and
in rodents, the SRD establishes reciprocal connections with the
periaqueductal gray (Morgan et al., 1992). Thus, this is a plausible
TABLE 3 | Treatment effect on HPT and AUECVAS between Groups: Mean ± SD, pre-intervention to post-intervention, mean difference with the confidence interval
(95% CI) and standardized mean difference (SMD) (n = 48).
Pre-intervention Post-intervention Mean difference
(pre-intervention –
post-intervention, 95% CI)
SMD
Heat pain threshold (◦C) (secondary)
a-tDCS/remifentanil 43.54 (3.13) 46.20 (2.80) −2.66 (−1.35 to −3.97)a 0.85
s-tDCS/remifentanil 42.63 (1.95) 43.35 (2.04) −0.72 (−0.35 to −1.79)b 0.37
a-tDCS/saline 43.44 (2.62) 45.17 (3.00) −1.73 (−0.90 to −2.56)a 0.66
s-tDCS/saline 43.72 (2.55) 43.50 (2.32) 0.22 (−1.15 to 0.70)c 0.09
P-valueU 0.02
Ice-water pain test (IPT) [area-under-the-time-response curve (AUC)] (secondary)
a-tDCS/remifentanil 952.85 (139.06) 777.66 (223.65) −175.19 (−284.18 to −66.20)b,c 1.26
s-tDCS/remifentanil 1036.43 (90.02) 802.88 (184.71) −233.55 (−315.38 to −151.72)b,c 2.59
a-tDCS/saline 1020.10 (120.32) 1003.21 (127.54) −16.89 (−68.80 to 35.02)a 0.15
s-tDCS/saline 1003.31 (84.15) 1005.33 (76.64) 2.03 (−24.45 to 28.50)a 0.03
P-valueU 0.02
R2 = 0.39. Repetitive cold test (RCOLDT).
SD, standard deviation; CI, confidence interval; tDCS, transcranial direct current stimulation.
Standardized mean difference (SMD) [(post minus pre)/baseline standard deviation the baseline standard deviation (SD) of sham tDCS/saline]. The effect size was
interpreted as follows: small, 0.20; moderate, 0.50–0.60 and large, 0.80.
UComparisons between the a-tDCS+remifentanil, s-tDCS+remifentanil, a-tDCS+saline analgesia, s-tDCS+saline analgesia groups performed using MANCOVA.
Different superscripts (a, b, c) indicate significant difference among treatment groups after post hoc analysis adjusted by Bonferroni (P < 0.05).
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mechanism that may be involved in r-IH as observed in the
current study, which we can indirectly assess.
Also, the r-IH observed in our study are aligned with the
previous study, which measured the DNIC, in which exogenous
opioids suppressed the endogenous opioid system and led to an
increased sensitivity to pain (Ram et al., 2008). However, it is
pertinent to emphasize that the greater pain score observed when
individuals received remifentanil, without an anodal stimulation
of M1, may be explained by a lack of the counteracting effects
as described in the previous study using fMRI (Borsook and
Becerra, 2006). This indicates that anodal stimulation of the M1
activates the endogenous opioid system (DosSantos et al., 2014).
Apparently, another factor may be involved in this response,
such as genetic polymorphism as reported in an experiment
with healthy subjects after a single opioid administration (Jensen
et al., 2009) and in a group of cancer patients (Rakvåg et al.,
2005), which showed that after a single opioid administration, a
repeated painful stimulus produced a hyperalgesic effect, which
was associated with the COMT val158met polymorphism. The
hypothesis of the involvement of the opioidergic system in tDCS
is plausible if one considers that the endogenous opioid system
is one important target of motor cortex stimulation to treat
pain (Maarrawi, 2007). Accordingly, previous studies showed
that the density of opioid receptors predicted pain relief when
the motor cortex is stimulated either in those suffering chronic
or acute postoperative pain (Maarrawi et al., 2013). Similarly,
after a single session of anodal M1-tDCS a decreased binding
of the selective µ-opioid receptor agonist [11-C] Carfentanil in
pain-related regions (e.g., thalamus, precuneus, PAG, prefrontal
cortex and the anterior cingulate cortex) was observed in healthy
subjects (DosSantos et al., 2014) as well as in the injured subjects
(DosSantos et al., 2012). Therefore, the present results also
indicate the contribution of the endogenous opioid system in the
analgesic effects induced by M1-a-tDCS.
The central role of the glutamatergic system to induce OIH
may be due to an increase of glutamate available to NMDA
receptors by a decreased reuptake of glutamate (Lee et al.,
2011). However, in the human, this effect can be assessed only
indirectly by behavioral and psychophysical measures. Although
the neurobiological processes involved in the effect of a-tDCS
to modulate hyperalgesia induced by remifentanil is not clear,
we can at least propose that there is an improvement in the
dysfunction of the DPMS with tDCS treatment. Even though
this is a matter of intense debate, an antidromic modulation
of thalamocortical pathways occurs when the motor cortex is
stimulated, which plays a central role in the analgesia induced by
M1 to decrease pain-induced thalamic hyperactivity (Tsubokawa
et al., 1993). However, further studies are necessary to establish
the clinical relevance for tDCS counteracting hyperalgesia
induced by remifentanil.
It is important to address several issues concerning the
design of our study: First, we include males only to exclude the
influence of the cyclical fluctuation of gonadal steroids during
the menstrual cycle on pain threshold in females (Smith et al.,
2002). Second, when opioids are applied, the blinding can be
troublesome due to their side effects. Sedation might mainly
affect the pain scores and the reaction-time. These effects can
explain the higher rate of individuals guessing the intervention
correctly when they received remifentanil compared to subjects
who did not. However, sedation is an intrinsic property of
opioids. Thus, its effect was considered in the analysis to control
its possible confounding effect. Thereby, it is improbable that
unblinding changes the directions of our conclusions. Third,
using this experimental design to induce sensitization, the RR
of remifentanil induced hyperalgesia increased significantly,
similarly to the incidence reported in previous studies run
in clinical settings (Fletcher and Martinez, 2014). Thereby,
these results enforce the theory that remifentanil can induce
hyperalgesia and the a-tDCS can partially block this paradoxical
effect. Fourth, it is important to take into account that we used
a cutoff point in the percentage of increase NPS (0–10) to define
hyperalgesia based on a clinical criteria to define a clinical effect
with a minimal relevance (Dworkin et al., 2009). Fourth, tDCS
is a low-cost technique with a low incidence of minor adverse
effects. It is easy to apply and it is an efficient technical solution to
conduct blinded studies of both the patients and experimenters
(Gandiga et al., 2006). Finally, the greater reaction time in the
groups that received remifentanil compared to the others that not
received remifentanil can be explained by the sedation analgesia
effect of opioids. However, in the groups s-tDCS/remifentanil
and s-tDCS/saline, a lower HPT was observed compared to the
groups that received a-tDCS, either combined with remifentanil
or saline. In fact, this result is in agreement with previous
studies which showed that a-tDCS improved the pain threshold
(Vaseghi et al., 2015). On the other hand, the current results
are in disagreement with previous studies that showed a higher
sensitivity in the pain perception by the QST, either in patients
managed with long-term opioid therapy (Compton et al., 2001)
or after acute opioid dependence in non-addicted humans
(Compton et al., 2003). A possible reason to explain these
differences between our findings and previous studies is the type
of opioids, dose and sample characteristics.
CONCLUSION
These findings suggest that effects of a-tDCS prevent the
summation response induced by r-IH during rCOLDT, and also
that a-tDCS blocked the disengagement of DPMS. Thereby, they
revealed that tDCS could be a new approach at contra-regulating
paradoxical mechanisms involved in r-IH. In fact, these results
have physiological implications to support an understanding of
the mechanisms involved in the pathophysiology of r-IH as well
as supporting the development of new approaches to treat OIH.
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